Loading the session
Loading the session
Loading instrument
$174.13
+0.87%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 18:25 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
The 4 Nov 2026 gain of 6.7% was 3.9× its average daily move of 1.7% over the past year, and its largest one-day gain since 7 Aug 2026.
Daily closes, split-adjusted · as of 4 Nov 2026
1 month: +8.1% (SPY −1.6%, XLV +13.5%). 3 months: +3.7% (SPY −0.4%, XLV +15.5%). 1 year: +37.4% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ICUI, SPY and XLV · as of 4 Nov 2026
1.7M shares were sold short at the 15 Oct 2026 settlement, 6.9% of the 25.0M shares outstanding; covering them would take 7.8 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $172.62 was 5.8% above its 50-day average ($163.20) and 16.0% above its 200-day average ($148.76). It has closed above the 200-day for 107 sessions, since 4 Jun 2026. The 50-day average crossed above the 200-day on 13 Jul 2026, 81 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Closed at $172.62 on 4 Nov 2026: 10.5% below the 52-week high of $192.85 (7 Aug 2026) and 52.3% above the low of $113.37 (29 Apr 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
August 8, 2024
+24.27%November 7, 2023
−17.31%August 8, 2023
−16.59%